SavedAdd your journal

Journals / MN Oftalmoloji / 2005 / Cilt: 12 - Sayı: 1

Comparison of the efficiency of latanoprost added to the therapy in phakic eyes and pseudophakic eyes with posterior chamber intraocular lens

Fakik ve arka kamara göz içi lensli gözlerde tedaviye eklenen latanoprostun etkinliğinin karşılaştırılması

A. Çiğdem ALTAN
Tuğrul ALTAN
Zerrin BAYRAKTAR
Şükrü BAYRAKTAR
Hakan EREN
Hakan SİVRİKAYA
Ömer Faruk YILMAZ
Pages
22–26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Latanoprost added to ß-blockers or timolol maleate-dorzolamide combination in phakic and pseudophakic eyes with posterior chamber IOL has clinically important IOP lowering effect and this effect was not significantly different between the two groups

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the intraocular pressure (IOP) lowering effect of latanoprost added to ß-blockers or timolol maleate-dorzolamide combination in phakic and pseudophakic eyes with posterior chamber intraocular lens (IOL).
📊
Key Findings & Data:Materials and Methods: 41 pseudophakic (group 1), and 45 phakic (group 2) eyes of 59 patients were included in the study.
💡
Conclusion & Impact:Conclusion: Latanoprost added to ß-blockers or timolol maleate-dorzolamide combination in phakic and pseudophakic eyes with posterior chamber IOL has clinically important IOP lowering effect and this effect was not significantly different between the two groups
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Psödofaki · Adrenerjik beta-antagonistleri · Glokom

Abstract

Purpose: To evaluate the intraocular pressure (IOP) lowering effect of latanoprost added to ß-blockers or timolol maleate-dorzolamide combination in phakic and pseudophakic eyes with posterior chamber intraocular lens (IOL). Materials and Methods: 41 pseudophakic (group 1), and 45 phakic (group 2) eyes of 59 patients were included in the study. IOP readings taken with Goldmann applanation tonometer were recorded before and at the 1st month, 3rd month, 6th month,12th month and at the last visit after the initiation of latanoprost therapy . The IOPs were compared in both groups Results: There were no difference in age, corneal thickness, follow-up time, and the initial IOP between groups. Significant IOP drop was obtained in both groups with the addition of latanoprost and no significant change was observed during follow-up. There was no significant difference in the percentage of IOP drop in both groups. There was no significant difference in the percentage of IOP drop with the addition of latanoprost between the eyes having ß-blocker or timolol maleate-dorzolamide combination therapy (p>0.05). There was a significant correlation between the initial IOP and the percentage of IOP drop (p<0.001). Conclusion: Latanoprost added to ß-blockers or timolol maleate-dorzolamide combination in phakic and pseudophakic eyes with posterior chamber IOL has clinically important IOP lowering effect and this effect was not significantly different between the two groups

Özet

Amaç: Fakik ve arka kamara göziçi lensli (GİL) glokomlu gözlerde beta blokör veya timolol maleat-dorzolamid kombinasyonuna eklenen latanoprostun göziçi basıncını (GİB) düşürme etkinliğini incelemek. Gereç ve Yöntem: 59 hastanın 41'i psödofakik (grup1), 45'i fakik (grup2) 86 gözü incelendi. Beta blokör veya timolol maleat-dorzolamid kombinasyonu kullanan olgularda latanoprost eklenmeden önceki ve eklendikten sonra 1. ay, 3. ay, 6. ay, 12. ay ve son muayenelerinde Goldmann aplanasyon tonometri ile alınmış GİB'leri gruplar arasında karşılaştırıldı. Bulgular: Gruplar arasında yaş, kornea kalınlığı, takip süresi ve başlangıç GİB arasında fark yoktu. Latanoprost eklenmesiyle her 2 grupta anlamlı GİB düşüşü sağlandı ve takip boyunca anlamlı değişim olmadı. GİB düşüş yüzdesi açısından gruplar arasında fark yoktu. Latanoprostun beta blokör veya timolol maleat-dorzolamid kombinasyonuna eklenmesiyle sağlanan GİB düşüş yüzdesi açısından anlamlı fark yoktu (p>0.05). Başlangıç GİB yüksekliğiyle GİB düşüş miktarı arasında anlamlı bir ilişki gözlendi (p<0.001) Sonuç: Fakik ve arka kamara göziçi lensli açık açılı glokomlu gözlerde beta blokör veya timolol maleat-dorzolamid kombinasyonuna eklenen latanoprostun göziçi basıncını düşürmede klinik olarak önemli derecede etkili olduğu ve GİB düşüşü açısından 2 grup arasında istatistiksel olarak anlamlı fark olmadığı saptanmıştır.

🔖

Cite This Article

ALTAN, A. Ç., ALTAN, T., BAYRAKTAR, Z., BAYRAKTAR, Ş., EREN, H., SİVRİKAYA, H., YILMAZ, Ö. F. (2005). Comparison of the efficiency of latanoprost added to the therapy in phakic eyes and pseudophakic eyes with posterior chamber intraocular lens. MN Oftalmoloji, Cilt: 12 - Sayı: 1, 22–26. https://ajindex.com/articles/296061

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Sponsel WE, Mensah J, Kiel JW,et al. Effects of latanoprost and timolol-xe on hydrodynamics in the normal eye. Am J Ophthalmol 2000; 130:151-9.
  2. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandings on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 1997; 41 (suppl 2):69-75.
  3. Arıcı MK, Güler C, Topalkara A, Erdoğan H, Balkanlıoğlu S. Latanoprost'un oküler hipotansif ve normotansif hastalarda göziçi basıncına etkisi. T Oft Gaz 1998; 28:97-100.
  4. Greve EL, Rulo AH, Drance SM, Crichton AC, Mills RP, Hoyng PFJ. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: A revi­ew of short-term studies with three dose regimens of latano­ prost treatment. Surv Ophthalmol 1997; 41 (suppl 2): 89-92.
  5. Patelska B, Greenfield DS, Liebmann JM, Wand M, Kushnick H, Ritch R. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol 1997; 124:79-86.
  6. Rulo AH, Greve EL, Geijssen HC, Hoyng PFJ. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996; 103:1276-82.
  7. Hedman K, Watson PG, Aim A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 2002; 47 (suppl 1 ):65-76. Bito LZ. Prostaglandins: A new approach to glaucoma management with a new intriguing side effect. Surv Ophthalmol 1997; 41 (Suppl 2):1-14.
  8. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolizm: Implications for uveoskleral outflow. Survey Ophthalmol 1997; 41 (suppl 2):53-9.
  9. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis assosiated with latanoprost use. Ophthalmology 1,998; 105:263-8.
  10. Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol 2002; 133:393-7.
  11. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema assosiated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998; 126:602-4.
  12. Callanan D, Fellman RL, Savage JA. Latanoprost_assosiated cystoid macular edema. Am J Ophthalmol 1998;126:134-5.
  13. Wu G, Marrell A. Severe hypotony following cataract extraction in a patient on latanoprost. Eye 2000;14:915-6.
  14. Elgin U, İlhan B, Batman A, Gürsel R, Çankaya B, Zilelioğlu O. Primer açık açılı glokomda akşam veya sabah tek doz uygulanan latanoproştun göz içi basıncına etkisinin timolol maleat ile karşılaştırılması. T